Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 11/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | MC1R | Q01726 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5947759 | 0.92 | HTR2A (0.57) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL5947749 | 0.92 | HTR6 (0.67) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL5947731 | 0.92 | HTR2A (0.63) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL2540382 | 0.91 | HTR2A (0.73) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL5947727 | 0.90 | KMT2A (0.52) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL5947184 | 0.89 | HTR2A (0.70) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL5947626 | 0.89 | HTR2A (0.60) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL5148243 | 0.88 | HTR2A (0.59) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL5947156 | 0.88 | HTR2A (0.59) | HTR2AHTR1ADRD2HTR2CHTR7 | |
| SCHEMBL5947747 | 0.88 | KMT2A (0.71) | HTR2AHTR1ADRD2HTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | claimed |
| CN-1610547-A | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | LILLY CO ELI (US) | 2005-04-27 | — | — | CN | claimed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | HTR2A 5/4885HTR1A 6/4885DRD2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.